NUVA:NGS-NuVasive Inc.

EQUITY | Medical Devices | Nasdaq Global Select

Last Closing

USD 63.7

Change

+0.07 (+0.11)%

Market Cap

USD 3.17B

Volume

0.32M

Analyst Target

USD 67.93
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NuVasive Inc is a medical device company. The Company develops minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its currently-marketed product portfolio is focused on applications for spine fusion surgery.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-10-16 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

-0.78 (-0.56%)

USD 51.34B
ALGN Align Technology Inc

+0.02 (+0.01%)

USD 24.63B
BRKR Bruker Corporation

+0.08 (+0.09%)

USD 12.93B
PODD Insulet Corporation

+2.22 (+1.31%)

USD 11.49B
SWAV Shockwave Medical Inc

+3.02 (+0.94%)

USD 10.25B
MASI Masimo Corporation

+2.37 (+1.64%)

USD 7.14B
AXNX Axonics Modulation Technologie..

+0.07 (+0.10%)

USD 3.51B
IRTC iRhythm Technologies Inc

+0.24 (+0.21%)

USD 3.36B
QDEL Quidel Corporation

-0.32 (-0.66%)

USD 3.14B
LIVN LivaNova PLC

+0.07 (+0.13%)

USD 3.02B

ETFs Containing NUVA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 28.53% 78% C+ 79% B-
Dividend Return N/A N/A N/A N/A F
Total Return 28.53% 78% C+ 78% C+
Trailing 12 Months  
Capital Gain -5.71% 76% C+ 50% F
Dividend Return N/A N/A N/A N/A F
Total Return -5.71% 76% C+ 48% F
Trailing 5 Years  
Capital Gain 83.52% 63% D 76% C+
Dividend Return N/A N/A N/A N/A F
Total Return 83.52% 63% D 73% C
Average Annual (5 Year Horizon)  
Capital Gain 8.46% 58% F 63% D
Dividend Return 8.46% 58% F 59% D-
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) 25.08% 85% B 54% F
Risk Adjusted Return 33.75% 61% D- 55% F
Market Capitalization 3.17B 91% A- 87% B+

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 95.70 40% 16%
Price/Book Ratio 4.02 50% 28%
Price / Cash Flow Ratio 15.84 25% 23%
Price/Free Cash Flow Ratio 16.66 24% 17%
Management Effectiveness  
Return on Equity 6.38% 82% 59%
Return on Invested Capital 6.24% 68% 57%
Return on Assets 4.09% 86% 76%
Debt to Equity Ratio 72.20% 33% 31%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector